Ansari Ramandi Mohammad Mostafa, van den Broek Stan A J, Mecozzi Gianclaudio, Erasmus Michiel E, van Melle Joost P, Damman Kevin
University of Groningen, Department of Cardiology, University Medical Center Groningen, Groningen, the Netherlands.
University of Groningen, Department of Cardiothoracic Surgery, University Medical Center Groningen, Groningen, the Netherlands.
J Cardiol Cases. 2022 May 2;26(2):122-125. doi: 10.1016/j.jccase.2022.03.021. eCollection 2022 Aug.
Systemic right ventricular failure is a common finding in patients with transposition of the great arteries. Some of these patients require ventricular assist device implantation. We describe the feasibility of HeartMate 3 [Abbott, Illinois, United States] implantation in a patient with transposition of the great arteries, high human leukocyte antigen sensitization, and severe pectus excavatum using a two-stage approach.
1.To notice the challenges faced while implanting HeartMate 3 [Abbott, Illinois, United States] in patients with congenital heart disease and anatomical limitations.2.To understand that despite the difficulties, HeartMate 3 implantation is possible, worthwhile, and sometimes the only choice in a patient with end-stage heart failure and congenital heart disease.
系统性右心室衰竭在大动脉转位患者中很常见。其中一些患者需要植入心室辅助装置。我们描述了采用两阶段方法，在一名患有大动脉转位、高人类白细胞抗原致敏和严重漏斗胸的患者中植入HeartMate 3[美国伊利诺伊州雅培公司]的可行性。
1.注意在先天性心脏病和解剖学限制患者中植入HeartMate 3[美国伊利诺伊州雅培公司]时面临的挑战。2.理解尽管存在困难，但对于终末期心力衰竭和先天性心脏病患者，植入HeartMate 3是可行的、值得的，有时甚至是唯一的选择。
